Focus on Lung Cancer
“Today’s approvals further illustrate how a greater understanding of the underlying molecular pathways of a disease can lead to the development of targeted treatments.”
The U.S. Food and Drug Administration has approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.
Different types of treatments are available for people with non-small cell lung cancer. Surgery, radiation therapy, chemotherapy, targeted therapy, laser therapy, photodynamic therapy, cryosurgery, electrocautery, and watchful waiting are the nine standard treatments used for this cancer.
The American Lung Association has launched Facing Lung Cancer: Support from Day One, a new patient- and caregiver-focused, web-based lung cancer information resource. This online tool offers interactive features that address specific topics of interest for people living with lung cancer and their loved ones.